Total amount: € 0,00
Official Journal of the Italian Society of Angiology and Vascular Pathology
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,752
Online ISSN 1827-1618
Batra Hospital & Medical Research Center Department of Cardiology, New Delhi, India
Aim. The safety and efficacy of the second-generation paclitaxel-eluting stent with bioactive matrix Taxcor after implantation in de novo coronary lesions at 6 months is unknown.
Methods. In this single-center non-controlled study, 45 patients with mean de novo coronary lesions of 12.1±1.9 mm in length and mean reference diameter of 2.9±0.3 mm received the paclitaxel-eluting stent (Taxcor). Fifty stents were implanted. Clinical and angiographic follow-up were performed after 6 months. It was the first time that the Taxcor stent was applied in patients.
Results. Mean stent diameter was 3.0±0.3 mm and mean length 21.2±5.9 mm. Four patients did not consent to control angiography at 6 months. Mean minimal lumen diameter increased from 1.1±0.1 mm (pre-stent) to 2.7±0.3 mm (post-stent) and had slightly decreased to 2.4±0.6 mm at 6-month follow-up. Mean acute lumen gain was 1.6±0.3 mm. Mean reference-vessel diameter was 2.9±0.3 mm at all time points. Mean percentage-diameter stenosis decreased from 62.6%±5.6 (pre-stent) to 9.1±6.0% (post-stent) and had increased slightly to 18.4±6.5% after 6 months. Mean late lumen loss was 0.3±0.4 mm. All patients remained symptom-free during the 6-month follow-up with no cases of acute myocardial infarction or death reported. No procedure-related complications occurred and no acute or subacute stent thromboses were reported. Control angiography showed binary restenosis (percentage-diameter stenosis >50%) in one patient, in whom coronary intervention was performed subsequently.
Conclusion. The paclitaxel-eluting stent Taxcor appeared to be effective and safe up to 6 months following implantation.